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Abstract. Fungal metabolites continue to show promise as 
a viable class of anticancer agents. In the present study, we 
investigated the efficacy of the fungal metabolite, fusarochro-
manone (FC101), for its antitumor activities in glioblastomas, 
which have a median survival of less than two years and a poor 
clinical response to surgical resection, radiation therapy and 
chemotherapy. Using clinically applicable doses, we demon-
strated that FC101 induced glioblastoma apoptotic cell death 
via caspase dependent signaling, as indicated by the cleavage 
of poly(ADP-ribose) polymerase, glioblastoma (PARP). FC101 
also induced differential reactive oxygen species (ROS) levels 
in glioblastoma cells, contrasting a defined role of oxidative 
stress in apoptotic cell death observed with other fungal 
metabolites. Furthermore, the antitumorigenic effects of 
FC101 on tumor cell migration were assessed. Cell migration 
assays revealed that FC101 significantly reduced the migra-
tory capacity of glioblastomas, which are incredibly invasive 
tumors. Taken together, the present study establishes FC101 as 
a candidate anticancer agent for the cooperative treatment of 
glioblastomas.
Introduction
Fungal metabolites are naturally occurring compounds 
produced by fungi with known anticancer properties (1). This is 
supported by early studies on cytochalasins, fungal metabolites 
that have been shown to inhibit the growth and migration of 
prostate cancer cells (2), as a consequence of impairing the 
biophysical function of actin filaments by binding and capping 
their barbed ends, thus, preventing microfilament elongation. 
Additionally, secondary metabolites (phenolic compounds, 
melanins and lanostane-type triterpenoids) produced by 
the white rot fungus, Inonotus obliquus, have also exhibited 
antitumorigenic properties in breast, leukemia and gastric 
cancers (3-5). Collectively, these studies provide experimental 
evidence for the persistent exploration and utility of fungal 
metabolites as agents for the treatment of human cancers.
In the present study, we evaluated the efficacy of fusa-
rochromanone (FC101), a fungal metabolite produced by 
Fusarium equiseti (6), in glioblastoma, the most common and 
aggressive type of malignant primary brain tumor. To date, few 
studies have been performed that have assessed the efficacy of 
FC101 as an anticancer agent. However, experimental studies 
conducted by Furmanski et al (7) and Dréau et al (8) have 
demonstrated that FC101 inhibits the growth of breast cancer 
cells and the in vitro and in vivo growth of melanomas. In addi-
tion a recent study by our group [Mahdavian et al (unpublished 
data)] also demonstrated that FC101 exerts antitumor affects in 
prostate and bladder cancer, further establishing the anticancer 
activity of this fungal metabolite. To this end, although the 
usage of fungal metabolites as potential therapeutic agents 
for the treatment of glioblastomas has received little attention, 
in this study, we provide evidence of the antitumor effects of 
FC101 on glioblastoma cell proliferation through the promo-
tion of apoptotic cell death, as well as its antagonizing affects 
on glioblastoma cell migration.
Materials and methods
Cell conditions and reagents. U87, A172 and U251 glio-
blastoma cells were purchased from the American Type 
Culture Collection (ATCC; Manassas, VA, USA). All cell 
lines were maintained in Dulbecco's modified Eagle's 
medium-DMEM (Invitrogen, Grand Island, NY, USA) 
containing 10% fetal bovine serum (FBS; Invitrogen), 2 mM 
L-glutamine (Invitrogen), 100 nM MEM non-essential amino 
acids (Invitrogen) and penicillin-streptomycin (Invitrogen) 
at 37˚C and 5% CO2. FC101 was generously provided by 
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Crystal violet cell proliferation assay. The cells were plated 
in 24-well plates, treated with 10, 5, 2.5 and 1 µM FC101 and 
allowed to incubate for 48 h (vehicle controls were treated 
with PBS) for dose-response experiments. For time-course 
experiments, the cells were treated with 1 µM FC101 and 
allowed to incubate for 24, 48, 72 and 96 h. Subsequently, the 
tissue culture medium was removed, the cell monolayer was 
fixed with 100% methanol for 5 min and stained with 0.5% 
crystal violet in 25% methanol for 10 min. The cells were then 
washed 3 times for 5 min each with distilled water to remove 
excess dye and allowed to dry overnight at room temperature. 
The incorporated dye was then solubilized in 0.1 M sodium 
citrate (Sigma-Aldrich, St. Louis, MO, USA) in 50% ethanol. 
Subsequently, 100 µl of treated and control samples were 
transferred to 96-well plates and optical densities were read 
at 540 nm using an xMark Microplate absorbance spectropho-
tometer (Bio-Rad Laboratories, Hercules, CA, USA).
Cell motility. Motility assays were conducted according to the 
manufacturer's instructions (Cell Biolabs Inc., San Diego, CA, 
USA). A cell suspension containing 0.5-1.0x106 cells/ml was 
prepared in serum-free mediaum with the vehicle (PBS) or 
1 µM FC101, while 500 µl of medium containing 10% fetal 
bovine serum was added to the lower chamber of the migration 
plate. Cell suspension (300 µl) containing the vehicle or 1 µM 
FC101 was then added to the inside of each insert and allowed 
to incubate for 24 h at 37˚C and 5% CO2. Subsequently, the 
non-migratory cells were removed from the plate inserts (as per 
the manufacturer's instructions), and the migratory cells were 
counterstained, solubilized and the optical density densities 
were read at 560 nm using an xMark Microplate absorbance 
spectrophotometer (Bio-Rad Laboratories).
Measurement of reactive oxygen species (ROS; H2O2) genera-
tion. ROS assays were conducted in accordance with the 
manufacturer's instructions (Cell Biolabs Inc.). A serial dilu-
tion of H2O2 (0-100 µM) was prepared to generate a standard 
curve, while the U87 and A172 cells (1x107) were plated, 
exposed to 1 µM FC101 or the vehicle (PBS) for 24 h and soni-
cated. Standards and samples were then mixed with an aqueous 
working reagent (as per the manufacturer's instructions), incu-
bated on a shaker for 30 min at room temperature, and the 
optical densities were read at 595 nm with a xMark Microplate 
absorbance spectrophotometer (Bio-Rad Laboratories).
ELISA. The cells were plated and treated with 1 µM FC101 
for 24 h or the vehicle (PBS); the cells were then lysed with 
CelLytic M Cell lysis reagent (Sigma-Aldrich) and protein 
concentrations were determined using the Bradford method. 
Protein extracts were diluted to a final concentration of 20 µg/
ml in PBS, coated to the wells of a PVC microtiter plate, and 
allowed to incubate at 4˚C overnight. Wells containing protein 
antigen were then washed with PBS 3 times, blocked with 
5% non-fat dry milk in PBS for 2 h, and washed again with PBS 
2 times. Subsequently, incubation with α-actinin 1 (Abnova, 
Walnut, CA, USA) or α-actinin 4 (Abnova) antibodies was 
performed overnight at 4˚C followed by washing 4 times with 
PBS. Incubation with an HRP-conjugated secondary antibody 
was performed for 3 h, followed by 4 washes with PBS. TMB 
substrate solution (Thermo Fisher Scientific, Inc., Rockford, 
IL, USA) was added for 15 min followed by a stop reaction 
with 0.2 M sulfuric acid. An absorbance reading at 450 nm 
was performed with a xMark Microplate absorbance spec-
trophotometer (Bio-Rad Laboratories). Absorbance readings 
were normalized to FC101 and the vehicle-treated samples 
that were processed with secondary antibody only. 
Western blot analysis. The cells were plated and treated with 
1 µM FC101 for 24 h or the vehicle (PBS), rinsed with PBS, 
and lysed with CelLytic M Cell lysis reagent (Sigma-Aldrich). 
Protein concentrations were subsequently determined using 
the Bradford method. Proteins were separated by SDS-PAGE 
in 8% polyacrylamide gels, then transferred to PVDF 
membranes. For immunoblotting, the PVDF membranes were 
incubated with poly(ADP-ribose) polymerase (PARP) and 
caspase-9 antibodies (Cell Signaling Technology, Danvers, 
MA, USA) recognizing target proteins overnight at 4˚C. The 
membranes were then incubated with an HRP-conjugated 
secondary antibody (1:2,000) for 1 h at room temperature, 
analyzed using the enhanced chemiluminescence (ECL) 
detection system (Thermo Fisher Scientific) and visualized 
by autoradiography. Tubulin (1:5,000) was used as a loading 
control.
Results
Antiproliferative effects of FC101 on glioblastomas. Our initial 
experiments evaluated the effects of FC101 on glioblastoma 
cell proliferation in dose-response experiments that showed 
that FC101 (10, 5, 2.5 and 1 µM) decreased the proliferative 
capacity of the U87, A172 and U251 cells (Fig. 1). The most 
demonstrative effects of FC101 in dose-response experiments 
were observed in the U251 cells which displayed a statistically 
significant decrease (P<0.05) in cell proliferation, even when 
treated with the lowest dose of 1 µM FC101, as compared to 
the vehicle-treated control cells (Fig. 1). To further assess the 
effects of FC101 on glioblastoma cell proliferation, time-course 
experiments were performed in which the cells were treated 
with 1 µM FC101 and examined over a 4-day period (Fig. 2). 
Consistent with the results from the dose-response experi-
ments, time-course analysis also revealed that FC101 reduced 
the proliferation of the glioblastoma cells, as evidenced by a 
pronounced decrease in cell proliferation 96 h post-FC101 
exposure, as compared to the vehicle-treated control cells 
examined at the same time point (Fig. 2). Additionally, ANOVA 
analysis of the time-course data revealed that the statistically 
significant (P<0.05) decrease observed in glioblastoma cell 
proliferation following treatment with FC101 was likely a 
consequence of a cytotoxic cellular response. This was deter-
mined by comparing glioblastoma cell viability at day 0 and 
4 days post-FC101 exposure, which showed a 31, 66 and 82% 
decrease in U87, A172 and U251 cell proliferation, respectively 
(Fig. 2). These data are in accordance with those of previous 
studies on FC101 in melanomas and breast cancer (7,8), as well 
as with those of studies conducted on glioblastomas with the 
fungal metabolites, ophiobolin A (9) and fumonisin B1 (10-12) 
that also induced cytotoxic cellular responses.
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FC101 induces glioblastoma cell death via apoptosis. To 
determine the mechanisms underlying the cytotoxic cellular 
response described above, we assessed the involvement of 
programmed cell death-associated signaling proteins and 
oxidative stress-related molecules in response to FC101. 
PARP, an enzymatic protein that plays a role in DNA 
repair and a downstream target of caspases, which mediate 
programmed cell death, was examined as an indicator 
of apoptosis in glioblastoma cells treated with FC101. 
Immunoblotting procedures revealed that the glioblastoma 
cells exposed to 1 µM FC101 produced cleaved PARP protein 
expression, a marker of cells undergoing apoptosis (Fig. 3), 
while no changes in caspase-9 protein expression, an initiator 
caspase, were observed (Fig. 3). Additionally, ROS, known 
inducers of death receptor and mitochondrial-mediated apop-
tosis in cancer cells, were also examined as a mechanistic 
contributor to FC101-induced glioblastoma cell death. To this 
end, we observed a modest increase in the hydrogen peroxide 
concentration in the A172 cells treated with FC101 as 
compared to the vehicle-treated control cells, while the U251 
cells displayed a decrease in hydrogen peroxide concentration 
following treatment with FC101 (Fig. 4). Taken together, these 
data demonstrate that FC101 induces a differential oxidative 
stress response that is cell type-dependent and that this fungal 
metabolite promotes apoptotic cell death in glioblastoma cells 
via caspase signaling. 
Inhibition of glioblastoma cell migration. Glioblastomas are 
highly invasive tumors that ultimately result in high rates of 
disease recurrence. Therefore, in this study, we analyzed the 
ability of FC101 to affect glioblastoma cell migration and 
structural proteins involved in this cellular process. α-actinin 1 
and 4, actin-binding proteins with an established role in cell 
migration (13,14) and shown to be expressed at high levels 
in glioblastomas as compared to normal brain tissue (14), 
were examined in the FC101-treated glioblastoma cells. 
Figure 1. Fusarochromanone (FC101) inhibits glioblastoma cell proliferation. 
Vehicle-treated control cells (black bars); and cells treated with 10 µM (white 
bars); 5 µM (medium gray bars); 2.5 µM (light gray bars); 1 µM (dark gray 
bars). Data shown are representative of 3 independent experiments performed 
in duplicate (means ± SE) showing similar results (*P<0.05).
Figure 2. Time-course analysis of fusarochromanone (FC101)-treated glioblas-
toma cells. Glioblastoma cells underwent cytotoxity-associated cell death in 
response to 1 µM FC101 (square), as compared to the vehicle-treated control 
cells (diamond). Shown is an experiment representative of 3 independent 
experiments performed in duplicate (means ± SE) that displayed similar results. 
Figure 3. Fusarochromanone (FC101) induces apoptotic cell death. FC101 pro-
moted programmed cell death as indicated by the expression of cleaved PARP 
in the A172 and U251 cells treated with 1 µM FC101 for 24 h. Immunoblots 
shown are representative of 3 independent experiments that showed similar 
results.
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Using immunoenzyme linked assays, a moderate increase in 
α-actinin 1 and 4 expression was observed in the U251 cells 
exposed to FC101 when compared to the vehicle-treated 
control cells, while a diminutive decrease in α-actinin 1 
and 4 expression was observed in the A172 cells treated with 
FC101 (Fig. 5). Subsequently, cell migration assays revealed 
that 1 µM FC101 induced a 46% decrease (P<0.05) in glioblas-
toma cell migration as compared to the vehicle-treated control 
cells (Fig. 6). These results are in accordance with the findings 
of a recent study by Bury et al (15), that also showed that the 
fungal metabolite, fusicoccin A, impaired the migratory and 
invasion ability of glioblastoma cells.
Discussion
Fungal metabolites are emerging as promising anticancer 
agents for the treatment of human cancers, in part, since they 
are naturally derived products. However, the utility of meta-
bolic products from fungi as adjuvant or neoadjuvant agents 
for the treatment of brain tumors, specifically glioblastomas, 
has received little attention. To date, the most well character-
ized fungal metabolite exhibiting cytotoxic anticancer activity 
in glioblastomas is the fumonisin, fumonisin B1, which exerts 
its biological effects by interfering with sphingolipid metabo-
lism (10-12). Additionally, studies on the fungal metabolites, 
brefeldin A and ophiobolin A, which impair the structure 
and functions of the Golgi apparatus and calmodulin, respec-
tively, have also shown that they promote glioblastoma cell 
death (9,16). Collectively, these studies establish the cytotoxic 
antitumor effects of fungi-produced metabolites in glioblas-
tomas by affecting a range of biological processes.
In this study, we demonstrated that the fungal metabolite, 
FC101, exhibited antitumorigenic affects in glioblastomas as 
a consequence of inducing cell death. This was supported by 
cell proliferation data from the present study that displayed an 
IC90 in glioblastomas treated with 1 µM FC101 and examined 
4 days later. Our findings are in accordance with those from 
other studies on breast, melanoma and bladder cancers, that 
also showed that therapeutic applicable concentrations of 
Figure 4. Detection of ROS in A172 (triangle) and U251 (square) cells treated 
with 1 µM fusarochromanone (FC101) for 24 h as determined by measuring 
H2O2 concentration.  H2O2 standard serial dilution (diamond); vehicle-treated 
control cells (solid symbols); cells treated with 1 µM FC101 (open symbols). 
Data displayed is an average of 3 separate independent experiments. 
Figure 6. Fusarochromanone (FC101) impairs glioblastoma cell migration. 
Glioblastoma cell migration was significantly (*P<0.05) diminished in the 
U251 cells treated with 1 µM FC101 for 24 h. Data shown are representative 
of 3 independent experiments performed in duplicate (means ± SE) showing 
similar results.(A) Vehicle-treated control cells (black bars); (B) cells treated 
with 1 µM FC101 for 24 h (white bars).
Figure 5. ELISA of α-actinin 1 and 4 (α-act1 and α-act4) in A172 and U251 
cells 24 h post-exposure to 1 µM fusarochromanone (FC101). Data displayed 
are an average (means ± SE) of 3 separate independent experiments. Vehicle-
treated control cells (black bars); cells treated with 1 µM FC101 for 24 h 
(white bars). 
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FC101 were effective at promoting tumor cell killing in these 
human cancers (7,8). In this study, it was also determined that 
FC101 induced caspase-dependent apoptotic glioblastoma 
cell death, as indicated by PARP cleavage, a caspase target. 
This is consistent with data from other studies on melanomas 
and breast cancer, that also demonstrated caspase-dependent 
apoptosis as the underlying mechanism of tumor cell death 
observed in these cancers in response to FC101 [(8) and study 
by Mahdavian et al (unpublished data)]. Although PARP 
cleavage provided substantial evidence that FC101 promoted 
caspase-dependent apoptotic glioblastoma cell death, changes 
in caspase-9 protein expression were not detected. The lack 
of an affect on caspase-9 expression supports the notion that 
FC101 does not induce apoptotic cell death in glioblastomas 
via an intrinsic mechanism, as suggested in in another study of 
ours [Mahdavian et al (unpublished data)], which showed that 
FC101 had no effect on intrinsic apoptotic pathway proteins 
(BAD, BAK and BAX) in breast cancer cells. In addition to 
caspase signaling, oxidative stress has also been shown to act 
as a mechanistic contributor of fungal metabolite-induced 
apoptotic cell death (10,11,17,18). Stockmann-Juvala et al (10) 
and Chaudhari et al (17) demonstrated that fumonisin B1 and 
the trichothecene, T-2 toxin, elicited apoptotic cell death as 
a consequence of increased ROS production and reduced 
glutathione levels in cervical cancer and glioblastomas, 
respectively. However, the assessment of oxidative stress in our 
study revealed differential ROS levels in the A172 and U251 
glioblastoma cells treated with FC101 as compared to the 
control-treated cells, suggesting that variations in the genetic 
backgrounds of these cells likely contribute to the divergent 
responses observed and the role of oxidative stress in FC101-
induced apoptotic glioblastoma cell death.
In this study, we further demonstrated that FC101 also 
exhibits antitumor properties in glioblastomas by abrogating 
cell migration, a cell behavior that contributes to the metastatic 
invasiveness of human cancers, ultimately leading to disease 
recurrence. This observation is consistent with recent studies on 
the fungal metabolites, fusicoccin A and chaetoglobosin A that 
also had antimigratory effects on glioblastoma and leukemia 
cells which were attributed to the impairment of the actin 
cytoskeleton (15,19). However, in this study, the analysis here of 
α-actinin 1 and 4, structural elements of the actin cytoskeleton 
with well-characterized roles in cell migration were minimally 
affected by exposure to FC101 (13,14). It should be stated that 
although FC101 appeared to have little affect on α-actinin 1 
and 4, the disruption of subcellular actin filament structures 
(leading edge, trailing edge) important for cell migration may 
underlie the affects of FC101 on glioblastosma cell migration, 
even in the absence of significant changes in protein expression. 
Additionally, the antimigratory response of glioblastomas to 
FC101 may be causally related to the down-regulation of metal-
loproteinases, as observed in osteosarcomas and mesothelioma 
cells treated with the fungal metabolites, 3-O-methylfunicone 
and fucoxanthin(20,21). Furthermore, to the best of our knowl-
edge, this is the first study that illustrates the antimigratory 
effects of FC101 on tumor cells.
In the present study, we demonstrate the effectiveness of 
FC101 as an anticancer agent in glioblastomas, expanding 
its potential therapeutic utility for the treatment of human 
cancers. The prospective application of FC101 for the treat-
ment of cancer is furthered by experimental studies that 
demonstrate that cancer cells are more sensitive to this fungal 
metabolite than normal tissue (7,8), suggesting that FC101 
circumvents normal tissue toxicity. This therapeutic character-
istic of FC101 is particularly advantageous when considering 
neurotoxicity is often a limiting factor for chemotherapeutic 
drugs used for the treatment of glioblastomas. Additional 
caveats to the clinical treatment of these tumors is their thera-
peutic resistance attributed in part to high recurrence rates that 
have made combinatorial therapy approaches essential for the 
management and treatment of this disease. FC101 represents a 
novel compound that can be explored for its therapeutic appli-
cations as a combinatorial agent that augments surgical and 
radiotherapy approaches for the treatment of glioblastomas.
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